Diogo Mendes1, Carlos Alves1,2, Nuno Silverio3, Francisco Batel Marques1,2. 1. Center for Health Technology Assessment and Drug Research, Association for Innovation and Biomedical Research on Light and Image, Coimbra, Portugal. 2. Laboratory of Social Pharmacy and Public Health, School of Pharmacy, University of Coimbra, Coimbra, Portugal. 3. Merck S.A., Algés, Portugal.
Abstract
BACKGROUND: Patients with undiagnosed hypothyroidism are not treated for the disease and are at high risk of developing serious complications, with major impact on public health. There is a need to systematically review the available evidence on this topic. OBJECTIVE: To identify the prevalence of undiagnosed hypothyroidism in Europe. METHODS: A systematic review of the literature (Medline, EMBASE, and Cochrane Central) was performed to identify epidemiological studies on the prevalence of undiagnosed hypothyroidism among European populations published between January 2008 and April 2018. The Newcastle-Ottawa Scale was used to assess the methodological quality of the included studies. Random-effects meta-analyses were performed to pool estimates of proportions (with 95% confidence intervals [CIs]) of undiagnosed (1) subclinical, (2) overt, and (3) total hypothyroidism. RESULTS: The search returned 15,565 citations (4,526 duplicates). Twenty papers were included in the study. Fourteen and 6 studies were of good and moderate methodological quality, respectively. The results of the meta-analyses were as follows for the prevalence of undiagnosed hypothyroidism: subclinical, 4.11% (95% CI 3.05-5.31%, I<sup>2</sup> = 99.32%); overt, 0.65% (95% CI 0.38-0.99%, I<sup>2</sup> = 96.67%); and total, 4.70% (95% CI 2.98-6.79%, I<sup>2</sup> = 99.53%). According to the sensitivity analysis, the prevalence of hypothyroidism tends to be higher in female patients, in those aged ≥65 years, among studies with lower sample sizes, in those with thyroid-stimulating hormone levels <4.5 mIU/L, and in Eastern and Southern Europe. CONCLUSIONS: The current evidence suggests that a considerable proportion of the European population has hypothyroidism, particularly subclinical hypothyroidism, which is undiagnosed. This issue deserves further investigation because of possible deleterious consequences for public health.
BACKGROUND: Patients with undiagnosed hypothyroidism are not treated for the disease and are at high risk of developing serious complications, with major impact on public health. There is a need to systematically review the available evidence on this topic. OBJECTIVE: To identify the prevalence of undiagnosed hypothyroidism in Europe. METHODS: A systematic review of the literature (Medline, EMBASE, and Cochrane Central) was performed to identify epidemiological studies on the prevalence of undiagnosed hypothyroidism among European populations published between January 2008 and April 2018. The Newcastle-Ottawa Scale was used to assess the methodological quality of the included studies. Random-effects meta-analyses were performed to pool estimates of proportions (with 95% confidence intervals [CIs]) of undiagnosed (1) subclinical, (2) overt, and (3) total hypothyroidism. RESULTS: The search returned 15,565 citations (4,526 duplicates). Twenty papers were included in the study. Fourteen and 6 studies were of good and moderate methodological quality, respectively. The results of the meta-analyses were as follows for the prevalence of undiagnosed hypothyroidism: subclinical, 4.11% (95% CI 3.05-5.31%, I<sup>2</sup> = 99.32%); overt, 0.65% (95% CI 0.38-0.99%, I<sup>2</sup> = 96.67%); and total, 4.70% (95% CI 2.98-6.79%, I<sup>2</sup> = 99.53%). According to the sensitivity analysis, the prevalence of hypothyroidism tends to be higher in female patients, in those aged ≥65 years, among studies with lower sample sizes, in those with thyroid-stimulating hormone levels <4.5 mIU/L, and in Eastern and Southern Europe. CONCLUSIONS: The current evidence suggests that a considerable proportion of the European population has hypothyroidism, particularly subclinical hypothyroidism, which is undiagnosed. This issue deserves further investigation because of possible deleterious consequences for public health.
Authors: Elizabeth H Hoogendoorn; Ad R Hermus; Femmie de Vegt; H Alec Ross; Andre L M Verbeek; Lambertus A L M Kiemeney; Dorine W Swinkels; Fred C G J Sweep; Martin den Heijer Journal: Clin Chem Date: 2005-10-27 Impact factor: 8.327
Authors: D G Tomov; B A Levterova; V N Mihaylova; D M Troev; M Z Miteva; M M Orbetzova Journal: Acta Endocrinol (Buchar) Date: 2021 Oct-Dec Impact factor: 1.104
Authors: Chubalemla Longkumer; Chandan Kr Nath; Bhupen Barman; Alice Abraham Ruram; Vizovonuo Visi; M D Yasir; Merrycka Agitok Sangma Journal: J Family Med Prim Care Date: 2020-09-30
Authors: D A Niculescu; R Attanasio; L Hegedüs; E V Nagy; R Negro; E Papini; P Perros; C Poiana Journal: Acta Endocrinol (Buchar) Date: 2020 Oct-Dec Impact factor: 0.877
Authors: Laszlo Hegedüs; Antonio C Bianco; Jacqueline Jonklaas; Simon H Pearce; Anthony P Weetman; Petros Perros Journal: Nat Rev Endocrinol Date: 2022-01-18 Impact factor: 47.564
Authors: G Lisco; A De Tullio; E Jirillo; V A Giagulli; G De Pergola; E Guastamacchia; V Triggiani Journal: J Endocrinol Invest Date: 2021-03-25 Impact factor: 4.256